^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vectibix (panitumumab)

    i
    Company:
    Amgen, Dr. Reddy’s, Takeda
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) (NCT05638295)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/01/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • KRAS
    |
    Vectibix (panitumumab) • Lumakras (sotorasib)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/07/2023
    Primary completion :
    07/01/2030
    Completion :
    07/01/2030
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • Tasigna (nilotinib) • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical
    Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) (NCT02980510)
    Phase 2
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/01/2016
    Primary completion :
    12/01/2025
    Completion :
    01/01/2026
    KRAS • RAS
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (NCT06011772)
    Phase 1
    Roswell Park Cancer Institute
    Suspended
    Last update posted :
    02/19/2025
    Initiation :
    12/04/2023
    Primary completion :
    12/04/2025
    Completion :
    12/04/2026
    KRAS • BRAF • RAS
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (NCT05845450)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    05/11/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2028
    HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1
    |
    HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) (NCT04787341)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/15/2020
    Primary completion :
    06/15/2025
    Completion :
    12/15/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (CodeBreak101) (NCT04185883)
    Phase 1
    Amgen
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/17/2019
    Primary completion :
    04/29/2026
    Completion :
    03/13/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases (CAIRO5) (NCT02162563)
    Phase 3
    Dutch Colorectal Cancer Group
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/01/2014
    Primary completion :
    07/01/2022
    Completion :
    01/01/2025
    BRAF • RAS
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (NCT01814501)
    Phase 2
    John Hays
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2013
    Primary completion :
    08/06/2018
    Completion :
    08/06/2018
    KRAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer (VICTORIA) (NCT06714357)
    Phase 2
    National Cancer Institute, Naples
    Not yet recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/01/2025
    Primary completion :
    12/20/2026
    Completion :
    06/20/2027
    BRAF
    |
    Vectibix (panitumumab) • irinotecan
    CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (CENDIFOX) (NCT05121038)
    Phase 1/2
    Anup Kasi
    Active, not recruiting
    Last update posted :
    12/17/2024
    Initiation :
    10/20/2021
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    BRAF
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study (NCT06575127)
    Phase 2
    Al-Azhar University
    Recruiting
    Last update posted :
    08/28/2024
    Initiation :
    08/17/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    KRAS • BRAF
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE-2) (NCT06509126)
    Phase 3
    National Cancer Institute, Naples
    Recruiting
    Last update posted :
    07/19/2024
    Initiation :
    06/12/2024
    Primary completion :
    01/01/2028
    Completion :
    06/01/2028
    BRAF
    |
    5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (NCT06194877)
    Phase 1
    MapKure, LLC
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    04/18/2024
    Primary completion :
    05/24/2027
    Completion :
    05/24/2027
    BRAF
    |
    Vectibix (panitumumab) • brimarefenib (BGB-3245)
    Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (PULSE) (NCT03992456)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    04/24/2020
    Primary completion :
    12/01/2023
    Completion :
    10/07/2024
    EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA
    |
    KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type
    |
    Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC (NCT03442569)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    03/09/2018
    Primary completion :
    09/21/2020
    Completion :
    12/22/2024
    KRAS • BRAF • MLH1 • MSH6 • MSH2
    |
    KRAS wild-type • NRAS wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Vectibix (panitumumab)
    Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300) (NCT05198934)
    Phase 3
    Amgen
    Active, not recruiting
    Last update posted :
    05/13/2024
    Initiation :
    04/19/2022
    Primary completion :
    03/12/2025
    Completion :
    03/12/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Vectibix (panitumumab) • Lumakras (sotorasib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (NCT04587128)
    Phase 2
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    10/19/2020
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    KRAS • BRAF • NRAS • MSI
    |
    BRAF mutation • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) (NCT03043950)
    Phase N/A
    iOMEDICO AG
    Completed
    Last update posted :
    04/24/2024
    Initiation :
    01/25/2017
    Primary completion :
    01/17/2024
    Completion :
    01/17/2024
    RAS
    |
    5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer (NCT02876107)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    10/06/2016
    Primary completion :
    10/31/2025
    Completion :
    10/31/2025
    HER-2 • NODAL
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    carboplatin • paclitaxel • Vectibix (panitumumab) • doxorubicin hydrochloride • cyclophosphamide
    A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (NuTide:302) (NCT03428958)
    Phase 1/2
    NuCana plc
    Completed
    Last update posted :
    04/03/2024
    Initiation :
    10/16/2018
    Primary completion :
    03/19/2024
    Completion :
    03/21/2024
    KRAS • BRAF
    |
    BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
    Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (HAITI) (NCT06332079)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    03/13/2024
    Primary completion :
    11/01/2026
    Completion :
    02/01/2027
    BRAF
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • irinotecan
    Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) (NCT01910610)
    Phase 3
    GERCOR - Multidisciplinary Oncology Cooperative...
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    10/30/2013
    Primary completion :
    07/13/2023
    Completion :
    12/01/2024
    KRAS • NRAS
    |
    NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (NCT05007132)
    Phase 2
    Dominik Paul Modest
    Recruiting
    Last update posted :
    02/15/2024
    Initiation :
    12/17/2021
    Primary completion :
    12/01/2029
    Completion :
    12/01/2032
    KRAS • NRAS
    |
    RAS mutation • RAS wild-type • KRAS exon 2 mutation
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)
    Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer (REVERCE II) (NCT04117945)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    03/03/2020
    Primary completion :
    02/28/2024
    Completion :
    03/31/2025
    KRAS • BRAF
    |
    BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan • Datalai (cetuximab biosimilar)
    Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial (NCT05468892)
    Phase 2
    University of Campania "Luigi Vanvitelli&q...
    Completed
    Last update posted :
    02/01/2024
    Initiation :
    10/29/2019
    Primary completion :
    05/31/2022
    Completion :
    06/30/2022
    KRAS
    |
    KRAS wild-type • KRAS exon 2 mutation
    |
    Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)
    Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (CRC01) (NCT06226857)
    Phase 3
    City Clinical Oncology Hospital No 1
    Recruiting
    Last update posted :
    01/29/2024
    Initiation :
    01/17/2024
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin
    Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC (NCT02593175)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/18/2024
    Initiation :
    08/26/2016
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    HER-2 • ER • PGR
    |
    carboplatin • paclitaxel • Vectibix (panitumumab)
    Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) (NCT03635021)
    Phase 3
    Spanish Cooperative Group for the Treatment of ...
    Active, not recruiting
    Last update posted :
    12/28/2023
    Initiation :
    10/15/2018
    Primary completion :
    06/28/2025
    Completion :
    06/28/2025
    KRAS • RAS
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (NCT03087071)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    12/21/2023
    Initiation :
    12/29/2017
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    KRAS • BRAF • NRAS • MAP2K1
    |
    KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type
    |
    Mekinist (trametinib) • Vectibix (panitumumab)
    A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (NCT01776307)
    Phase 2
    Sumitomo Pharma America, Inc.
    Completed
    Last update posted :
    11/15/2023
    Initiation :
    03/01/2012
    Primary completion :
    06/01/2018
    Completion :
    04/01/2020
    KRAS • RAS
    |
    RAS wild-type
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • capecitabine • napabucasin (BBI608)
    Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer (NCT05694936)
    Phase 2
    Australasian Gastro-Intestinal Trials Group
    Recruiting
    Last update posted :
    11/03/2023
    Initiation :
    01/23/2023
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    KRAS • NRAS
    |
    KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
    |
    Erbitux (cetuximab) • Vectibix (panitumumab)
    Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (PARADIGM) (NCT02394795)
    Phase 3
    Takeda
    Completed
    Last update posted :
    11/01/2023
    Initiation :
    05/29/2015
    Primary completion :
    01/14/2022
    Completion :
    01/14/2022
    KRAS • NRAS
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • levoleucovorin calcium
    A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer (NCT03206073)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/24/2023
    Initiation :
    12/07/2017
    Primary completion :
    09/24/2020
    Completion :
    06/30/2022
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Imjudo (tremelimumab-actl) • Pexa-Vec (pexastimogene devacirepvec)
    Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) (NCT02885753)
    Phase 3
    Federation Francophone de Cancerologie Digestive
    Recruiting
    Last update posted :
    08/17/2023
    Initiation :
    12/01/2016
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    KRAS • NRAS • RAS
    |
    KRAS mutation • NRAS mutation • RAS mutation • KRAS exon 2 mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME) (NCT03584711)
    Phase 2
    Federation Francophone de Cancerologie Digestive
    Active, not recruiting
    Last update posted :
    08/17/2023
    Initiation :
    04/26/2018
    Primary completion :
    04/01/2024
    Completion :
    12/01/2024
    ALK • RAS
    |
    RAS mutation
    |
    5-fluorouracil • Vectibix (panitumumab) • leucovorin calcium
    A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab (NCT05993455)
    Phase 2
    Korea University Anam Hospital
    Active, not recruiting
    Last update posted :
    08/15/2023
    Initiation :
    07/03/2023
    Primary completion :
    09/04/2023
    Completion :
    12/31/2023
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Vectibix (panitumumab) • Lumakras (sotorasib)
    P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (NCT01591421)
    Phase 1/2
    Canadian Cancer Trials Group
    Completed
    Last update posted :
    08/04/2023
    Initiation :
    09/06/2012
    Primary completion :
    09/30/2015
    Completion :
    11/12/2019
    KRAS • RAS
    |
    KRAS mutation • RAS mutation • RAS wild-type
    |
    Vectibix (panitumumab) • buparlisib (AN2025)
    Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer (NCT05177796)
    Phase 2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    07/28/2023
    Initiation :
    03/11/2022
    Primary completion :
    07/26/2023
    Completion :
    07/26/2023
    HER-2 • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Vectibix (panitumumab) • doxorubicin hydrochloride • cyclophosphamide • daunorubicin
    FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer (NCT04169347)
    Phase 2
    Criterium, Inc.
    Active, not recruiting
    Last update posted :
    07/27/2023
    Initiation :
    12/02/2019
    Primary completion :
    12/01/2024
    Completion :
    01/01/2025
    KRAS
    |
    KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (PanaMa) (NCT01991873)
    Phase 2
    AIO-Studien-gGmbH
    Completed
    Last update posted :
    06/14/2023
    Initiation :
    04/01/2014
    Primary completion :
    02/18/2023
    Completion :
    02/18/2023
    RAS
    |
    RAS wild-type
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium